Expert Review of Anti-infective Therapy最新文献

The ongoing challenge of prevention of pertussis in infants: what's new in 2024?

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-06 DOI: 10.1080/14787210.2025.2476010

Maria Gabriella Matera, Carlo Capristo, Vito de Novellis, Mario Cazzola

{"title":"The ongoing challenge of prevention of pertussis in infants: what's new in 2024?","authors":"Maria Gabriella Matera, Carlo Capristo, Vito de Novellis, Mario Cazzola","doi":"10.1080/14787210.2025.2476010","DOIUrl":"https://doi.org/10.1080/14787210.2025.2476010","url":null,"abstract":"Introduction: Pertussis, a respiratory disease caused primarily by Bordetella pertussis, is undergoing a resurgence despite decades of high rates of vaccination. The prevention of pertussis in infants presents several challenges, including the waning immunity of the acellular pertussis (aP) vaccine, the limited protection afforded to newborns before they complete the vaccine series, and the existence of gaps in maternal vaccination. Furthermore, the unwillingness or refusal of a considerable number of individuals, including some healthcare workers, to receive vaccinations represents another significant challenge.Areas covered: This narrative review provides an updated overview of the ongoing challenge of preventing pertussis in infants and discusses some possible solutions.Expert opinion: The ongoing challenge of preventing pertussis in infants is multifaceted. To address these challenging issues, a multi-pronged approach is required. This approach should be designed to address various barriers and increase uptake. It should include measures to strengthen maternal vaccination programs, ensure timely infant vaccinations, improve public education, and continue research into more effective vaccines with longer-lasting immunity.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-04 DOI: 10.1080/14787210.2025.2473044

Daniele Focosi, David J Sullivan, Massimo Franchini

引用次数: 0

Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-04 DOI: 10.1080/14787210.2025.2473077

Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione

{"title":"Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review.","authors":"Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione","doi":"10.1080/14787210.2025.2473077","DOIUrl":"10.1080/14787210.2025.2473077","url":null,"abstract":"Introduction: Antibiotics were originally developed to treat acute bacterial infections, and research studies focus their efforts on safety and efficacy in the short term; however, prolonged course of antibiotics has been documented in multiple clinical settings. The aim of this narrative review is to provide a new perspective on SAT and to discuss new therapeuticpossibilities.Areas covered: We discuss new clinical scenarios in which SAT could be considered. We provided a broad discussion about long-acting agents and new or repurposed oral agents as well as the use of OPAT with elastomeric pumps and an overview of the pipeline of new antifungals. Limitations of SAT are presented in this review and especially patients' adherence issues, possible spread of MDROs, possible rising of the incidence of Clostridioides difficile infections, drug-to-drug interactions and drug-related problems, cost-effectiveness evaluation issues.Expert opinion: Many research gaps are evident and further studies are needed. Above all, the efficacy and safety of SAT in the different clinical scenarios. Discovery of new molecules against MDROs and ongoing research on PK/PD variables as well as a better understanding of the relationship between SAT and the emergence of resistance could improve SAT usage and reduce the impact of DRPs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Past, present, and future perspectives on aztreonam and avibactam.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-03-04 DOI: 10.1080/14787210.2025.2473047

Karen Bush

{"title":"Past, present, and future perspectives on aztreonam and avibactam.","authors":"Karen Bush","doi":"10.1080/14787210.2025.2473047","DOIUrl":"10.1080/14787210.2025.2473047","url":null,"abstract":"Introduction: Aztreonam is a monobactam antibiotic approved in 1986 to treat infections caused by aerobic Gram-negative bacteria, but, together with cephalosporins, lost clinical utility due to the emergence of extended-spectrum β-lactamases (ESBLs) and novel (serine) carbapenemases. Avibactam was the first in a novel non-β-lactam β-lactamase inhibitor class to effectively inhibit these enzymes. It has been approved in combination with ceftazidime to treat Gram-negative infections caused by bacteria that produce AmpC, ESBLs and serine carbapenemases, and with aztreonam to treat patients infected with metallo-β-lactamase-producing enteric bacteria. Combinations of avibactam with ceftazidime and/or aztreonam have been used successfully to treat enteric pathogens producing multiple classes of β-lactamases.Areas covered: Development of aztreonam, avibactam, and avibactam combinations are placed into a historical perspective, based on both preclinical and clinical data. A search of MEDLINE (Ovid) was used to identify relevant literature.Expert opinion: Avibactam combined with ceftazidime and aztreonam in either dual or triple combinations provides the opportunity to treat previously untreatable Gram-negative infections that produce multiple β-lactamases. Aztreonam combinations should be particularly attractive, due to stability to metallo-β-lactamase hydrolysis and its safety advantage in treating penicillin-allergic patients. Other inhibitor combinations in development may challenge these combinations.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":4.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standard dose could be better! A multicenter study of tigecycline in patients with liver failure.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-26 DOI: 10.1080/14787210.2025.2472346

Jinlin Guo, Xinfeng Cai, Shan Wang, Hongping Wen, Jing Ren, Mi Zhou, Xingang Li, Xiaodan Yan, Shuangshuang Tian, Fang Zhang, Yanqin Liu, Wenjun Zhang, Yunyun Shao, Jianghong Cao, Xiaochun Liu, Kaixuan Hou, Dan Wei, Guan Lin

{"title":"Standard dose could be better! A multicenter study of tigecycline in patients with liver failure.","authors":"Jinlin Guo, Xinfeng Cai, Shan Wang, Hongping Wen, Jing Ren, Mi Zhou, Xingang Li, Xiaodan Yan, Shuangshuang Tian, Fang Zhang, Yanqin Liu, Wenjun Zhang, Yunyun Shao, Jianghong Cao, Xiaochun Liu, Kaixuan Hou, Dan Wei, Guan Lin","doi":"10.1080/14787210.2025.2472346","DOIUrl":"10.1080/14787210.2025.2472346","url":null,"abstract":"Background: High-dose (HD) tigecycline is often required for severe multidrug-resistant gram-negative infections in liver failure patients, despite package recommendations to halve the dose for those with severe liver impairment. This study evaluated the efficacy and safety of different tigecycline doses in this population.Research design and methods: A retrospective cohort of 192 patients with Child-Pugh grade C liver failure was divided into label-dose (LD), standard-dose (SD), and HD groups. Primary and secondary outcomes included microbial eradication, mortality, and adverse effects.Results: The SD group achieved higher microbial eradication than LD, with comparable efficacy to HD but fewer adverse events, such as fibrinogen requirements. High-dose treatment increased mortality risk (Hazard Ratio: 1.85, p = 0.062). Optimal microbial eradication and minimized adverse effects occurred with the SD group at 7 days of treatment.Conclusions: Standard-dose tigecycline offers a balanced approach to microbial eradication and safety, making it preferable in liver failure patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":4.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mistakes to avoid in the management of abdominal tuberculosis.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-23 DOI: 10.1080/14787210.2025.2468331

Abhirup Chatterjee, Daya Krishna Jha, Aravind Sekar, Vishal Sharma

{"title":"Mistakes to avoid in the management of abdominal tuberculosis.","authors":"Abhirup Chatterjee, Daya Krishna Jha, Aravind Sekar, Vishal Sharma","doi":"10.1080/14787210.2025.2468331","DOIUrl":"10.1080/14787210.2025.2468331","url":null,"abstract":"Introduction: The diagnosis and management of abdominal tuberculosis, i.e Gastrointestinal Tuberculosis (GITB) and tuberculous peritonitis (TBP) is challenging. Abdominal tuberculosis, presenting usually with abdominal pain, intestinal obstruction, and constitutional symptoms, is typically a paucibacillary condition. The diagnosis hinges on a correct interpretation of clinical, radiological, histological, biochemical, and microbiological findings as also appropriately assessing response to therapy.Areas covered: The authors review potential missteps that could occur in managing GITB and TBP sourced from published literature and clinical experience. These include avoiding excess use of tests with limited accuracy, understanding limitations of ascitic adenosine deaminase (ADA) and granulomas, avoiding empirical antitubercular therapy (ATT) where possible but also understanding that microbiological tests may not always be positive, and finally not to bank solely on subjective clinical responses but to use objective markers in assessing response to therapy. In addition, diagnosis of predisposing immunosuppressed states, attention to nutrition, appropriate management of sequelae with endoscopic dilatation/surgery, and early surgery when indicated are some of the additional issues discussed.Expert opinion: In future, a more secure diagnosis banking on the use of better microbiological tools, multiparameter-based models, artificial intelligence-based approaches, and use of advances in -omics-based approaches can improve diagnosis and avoid some missteps.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-19"},"PeriodicalIF":4.2,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The serological dilemma: rethinking syphilis treatment evaluation.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-18 DOI: 10.1080/14787210.2025.2467646

Jiangchen Yao, Peng Ling, Xuan Ding, Xiaohong Zhang, Ting Lin, Yongjian Xiao, Shuangquan Liu, Feijun Zhao

{"title":"The serological dilemma: rethinking syphilis treatment evaluation.","authors":"Jiangchen Yao, Peng Ling, Xuan Ding, Xiaohong Zhang, Ting Lin, Yongjian Xiao, Shuangquan Liu, Feijun Zhao","doi":"10.1080/14787210.2025.2467646","DOIUrl":"10.1080/14787210.2025.2467646","url":null,"abstract":"Introduction: Nontreponemal tests (NTT) constitute a significant method in syphilis detection, playing a crucial role in screening, diagnosing, and monitoring disease activity. However, recent discussions have cast doubt on the traditional belief that NTT are suitable for evaluating treatment efficacy, as inconsistencies between NTT results and syphilis treatment outcomes have been observed with some frequency.Areas covered: We have delineated the current status of serological methods for evaluating the therapeutic efficacy of syphilis treatment and summarized and discussed the exploration of biomarkers for syphilis therapy. A literature search was conducted in PubMed over all available dates for relevant published papers and conference abstracts with the search terms, 'Syphilis,' 'Treponema pallidum,' 'Serofast,' 'Treatment efficacy evaluation,' 'Nontreponemal,' 'RPR,' 'TRUST,' 'VDRL,' 'Neurosyphilis,' 'Pregnant syphilis,' 'Congenital syphilis,' 'Reinfection,' 'Cardiolipin,' 'Serology.'Expert opinion: Currently, the assessment of treatment efficacy through serological methods is limited to the use of the NTT. Therefore, it is imperative for clinicians to gain a deeper understanding of the significance and limitations of the NTT, as well as a focus on exploring more potential indicators for evaluating treatment efficacy.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":4.2,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current role of ceftobiprole in the treatment of hospital-acquired and community-acquired pneumonia: expert opinion based on literature and real-life experiences.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-05 DOI: 10.1080/14787210.2025.2461552

Ivan Gentile, Simone Giuliano, Silvia Corcione, Francesco Giuseppe De Rosa, Marco Falcone, Daniele Roberto Giacobbe, Alberto Enrico Maraolo, Claudio Maria Mastroianni, Alessandra Oliva, Renato Pascale, Carlo Tascini, Giusy Tiseo, Pierluigi Viale, Matteo Bassetti

{"title":"Current role of ceftobiprole in the treatment of hospital-acquired and community-acquired pneumonia: expert opinion based on literature and real-life experiences.","authors":"Ivan Gentile, Simone Giuliano, Silvia Corcione, Francesco Giuseppe De Rosa, Marco Falcone, Daniele Roberto Giacobbe, Alberto Enrico Maraolo, Claudio Maria Mastroianni, Alessandra Oliva, Renato Pascale, Carlo Tascini, Giusy Tiseo, Pierluigi Viale, Matteo Bassetti","doi":"10.1080/14787210.2025.2461552","DOIUrl":"10.1080/14787210.2025.2461552","url":null,"abstract":"Introduction: Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) are major global health challenges, with high morbidity and mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness of standard empirical antibiotics, highlighting the need for broader-spectrum agents that target also MDR organisms.Areas covered: This review summarizes findings from a PubMed search on the use of ceftobiprole in CAP and HAP. It highlights key features of ceftobiprole, including its mechanism of action and broad spectrum of activity against multiple MDR pathogens. Clinical data from randomized controlled trials and real-world studies underscore its non-inferiority to standard treatments, with favorable safety profile and high clinical cure rates even in challenging cases.Expert opinion: Ceftobiprole represents a valid option for the patients with CAP and HAP. Its main advantages include its broad spectrum of activity, making it a valuable therapeutic choice for treating polymicrobial infections, and its favorable safety profile, which makes it a good candidate in elderly patients with multiple comorbidities and polypharmacy. Caution is advised in patients at high risk of ESBL-producing organisms or MDR Pseudomonas aeruginosa infections, where combination therapy is recommended. Moreover, therapeutic drug monitoring is recommended to improve outcomes, particularly in complex clinical conditions.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":4.2,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on newer antifungals.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-04 DOI: 10.1080/14787210.2025.2461566

Karolina Akinosoglou, Despoina Papageorgiou, Charalambos Gogos, George Dimopoulos

引用次数: 0

Adult vaccinations against respiratory infections.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-31 DOI: 10.1080/14787210.2025.2457464

Antoni Torres, Catia Cilloniz, Marta Aldea, Guillermo Mena, José M Miró, Antoni Trilla, Ana Vilella, Rosario Menéndez

{"title":"Adult vaccinations against respiratory infections.","authors":"Antoni Torres, Catia Cilloniz, Marta Aldea, Guillermo Mena, José M Miró, Antoni Trilla, Ana Vilella, Rosario Menéndez","doi":"10.1080/14787210.2025.2457464","DOIUrl":"10.1080/14787210.2025.2457464","url":null,"abstract":"Introduction: Lower respiratory infections have a huge impact on global health, especially in older individuals, immunocompromised people, and those with chronic comorbidities. The COVID-19 pandemic highlights the importance of vaccination. However, there are lower rates of vaccination in the adult population that are commonly due to a missed opportunity to vaccinate. Vaccination offers the best strategy to prevent hospitalization, complications, and death caused by lower respiratory infections.Areas covered: In this review, the authors provide an overview of the vaccines for lower respiratory infections in the adult population. The review highlights the available data about the impact of vaccines on preventing respiratory infections, focusing on the pneumococcal vaccine, influenza vaccine, COVID-19 vaccines, and respiratory syncytial virus (RSV) vaccines. The authors discuss the currently available scientific evidence on the role of vaccines against respiratory infections. Finally, the authors review the current recommendations for vaccines in the adult population.Expert opinion: Scientific evidence on the effectiveness of vaccines against respiratory infections is important. An efficient implementation of adult immunization strategies will provide an opportunity to decrease the global burden of lower respiratory infections. Recognizing the existing vaccines and their recommendations for the adult population is essential to achieve a high vaccination rate in the population.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.2,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0